Catheter-Associated Urinary Tract Infection (CAUTI) Prevention Urology Products Global Market Report 2026

The catheter-associated urinary tract infection (CAUTI) prevention urology products market size has grown strongly in recent years. It will grow from $2.98 billion in 2025 to $3.23 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increasing prevalence of catheter-associated urinary tract infections, growing hospital and long-term care facility patient population, adoption of infection control protocols, rising awareness of urinary hygiene, expansion of urology-focused medical devices.

The catheter-associated urinary tract infection (CAUTI) prevention urology products market size is expected to see strong growth in the next few years. It will grow to $4.51 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to growing adoption of antimicrobial and smart catheters, increasing integration with patient monitoring systems, rising demand in home care settings, expansion of minimally invasive urology procedures, growing focus on regulatory compliance and infection prevention. Major trends in the forecast period include increasing adoption of antimicrobial urinary catheters, rising demand for closed system intermittent catheters, growing integration of catheter securement devices, expansion of smart foley catheters with monitoring features, rising focus on home care and long-term care catheter solutions.

The increasing rates of hospital-acquired infections are anticipated to drive the expansion of the catheter-associated urinary tract infection (CAUTI) prevention urology products market in the coming years. Hospital-acquired infection rates indicate how often patients develop infections during hospital stays that were neither present nor incubating at the time of admission. The surge in hospital-acquired infections is largely attributed to antimicrobial resistance, which enables pathogens to withstand standard treatments and spread more readily within healthcare environments. Catheter-associated urinary tract infection (CAUTI) prevention urology products aid in lowering hospital-acquired infection rates by reducing bacterial colonization and biofilm formation on indwelling catheters, thereby decreasing the likelihood of urinary tract infections in hospitalized patients. For example, in May 2024, the Center for Infectious Disease Research and Policy (CIDRAP), a US-based disease research organization, reported that nearly 4.3 million patients per year acquired at least one healthcare-associated infection in hospitals across the European Union and European Economic Area in 2022 and 2023. Consequently, the rising hospital-acquired infection rates are fueling the growth of the catheter-associated urinary tract infection (CAUTI) prevention urology products market.

Leading companies operating in the catheter-associated urinary tract infection (CAUTI) prevention urology products market are focusing on developing innovative solutions, such as female external catheter devices, to enhance patient comfort, reduce infection risk, and improve overall urinary care outcomes. A female external catheter device is a non-invasive medical device worn externally over the female genital area to collect urine safely and comfortably, helping manage urinary incontinence and minimize infection risk. For example, in January 2026, Wellspect HealthCare, a Sweden-based medical device company, launched Surity Female External Catheter, an innovative non-invasive urinary incontinence management product that supports women living with severe urinary incontinence and their caregivers. It is engineered to be easy to place, help prevent leakage, protect skin integrity, and support extended overnight use while integrating with compatible urine collection systems, addressing a significant gap in continence care where few options have existed. Its design emphasizes comfort, reliability, and predictable daily use in both home and healthcare settings as a contemporary alternative to indwelling catheters.

In April 2024, Medline Industries LP, a US-based healthcare company, entered into an agreement with Consure Medical to exclusively distribute the QiVi MEC male external urine management device in acute care settings throughout the United States. This partnership with Medline Industries LP is designed to improve patient care and minimize hospital-acquired infections by combining Medline’s comprehensive catheter and urology product portfolio with Consure Medical’s innovative external urine management technology. Consure Medical Inc. is a US-based medical device company that specializes in offering urology products specifically aimed at preventing CAUTI (catheter-associated urinary tract infection).

Major companies operating in the catheter-associated urinary tract infection (CAUTI) prevention urology products market are Cardinal Health Inc., Medtronic plc, Medline Industries Inc., Stryker Corporation, Becton, Dickinson Company, Boston Scientific Corporation, B. Braun Melsungen AG, Olympus Corporation, Nipro Corporation, Coloplast A/S, Teleflex Incorporated, Cook Medical LLC, ConvaTec Group PLC, Hollister Incorporated, Merit Medical Systems Inc., Amsino International Inc., Laborie Medical Technologies Inc., Cathetrix Inc., Bactiguard AB, Poiesis Medical Inc.

North America was the largest region in the catheter-associated urinary tract infection (CAUTI) prevention urology products market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the catheter-associated urinary tract infection (CAUTI) prevention urology products market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the catheter-associated urinary tract infection (CAUTI) prevention urology products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The catheter-associated urinary tract infection (CAUTI) prevention urology products market consists of sales of antimicrobial‑coated urinary catheters, closed urine drainage systems, intermittent catheters, external urine management devices, and catheter hygiene products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Catheter-associated urinary tract infection (CAUTI) prevention urology products are medical devices and tools specifically developed to lower the risk of urinary tract infections in patients who require catheterization. These products emphasize improved catheter handling, maintenance of urinary hygiene, and adherence to infection prevention protocols within healthcare settings.

The primary product types of catheter-associated urinary tract infection (CAUTI) prevention urology products include antimicrobial urinary catheters, intermittent catheters, foley catheters, catheter securement devices, and urine collection bags. Antimicrobial urinary catheters are designed with antimicrobial coatings to prevent bacterial colonization and reduce infection risks. They are offered in silicone, latex, hydrogel-coated, and silver alloy-coated materials. Applications include urinary incontinence management, acute surgical perioperative care, benign prostatic hyperplasia and obstructive urology, neurogenic bladder and spinal cord injury, and others, serving hospitals, long-term care facilities, home care settings, ambulatory surgical centers, and other end-users.

Tariffs on imported catheter materials, antimicrobial coatings, and medical device components are affecting the CAUTI prevention urology products market by raising production and procurement costs, particularly impacting antimicrobial catheters, Foley catheters, and urine collection bags. Regions such as North America, Europe, and Asia-Pacific, which rely heavily on imported devices and components, are most affected. While tariffs increase costs, they also encourage local manufacturing, promote regional supply chain resilience, and drive innovation in cost-effective, high-safety catheter solutions, benefiting long-term market growth.

The catheter-associated urinary tract infection (CAUTI) prevention urology products market research report is one of a series of new reports that provides catheter-associated urinary tract infection (CAUTI) prevention urology products market statistics, including catheter-associated urinary tract infection (CAUTI) prevention urology products industry global market size, regional shares, competitors with a catheter-associated urinary tract infection (CAUTI) prevention urology products market share, detailed catheter-associated urinary tract infection (CAUTI) prevention urology products market segments, market trends and opportunities, and any further data you may need to thrive in the catheter-associated urinary tract infection (CAUTI) prevention urology products industry. This catheter-associated urinary tract infection (CAUTI) prevention urology products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.